{"mainPropery":{"diseaseId":13103,"diseaseName":"Adult T-cell leukemia/lymphoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/13103/adult-t-cell-leukemialymphoma","synonyms":["ATLL","Adult T-cell leukaemia","Adult T-cell leukaemia/lymphoma (HTLV-1 positive)","Adult T-cell lymphoma"],"synonyms-with-source":[{"name":"ATLL","source":"Orphanet"},{"name":"Adult T-cell leukaemia","source":"NCI Thesaurus"},{"name":"Adult T-cell leukaemia/lymphoma (HTLV-1 positive)","source":"NCI Thesaurus"},{"name":"Adult T-cell lymphoma","source":"Leukaemia Foundation"}],"identifiers":[{"identifierType":"ORPHANET","identifierId":"86875"},{"identifierType":"ICD 10","identifierId":"C91.5"}]},"diseaseCategories":[{"diseaseTypeId":12,"diseaseTypeName":"Blood Diseases","source":"Orphanet"},{"diseaseTypeId":22,"diseaseTypeName":"Skin Diseases","source":"Orphanet"}],"organizations":[],"resource descriptions":[{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=86875' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":11075,"questionText":"What is adult T-cell leukemia/lymphoma?","answerText":"<strong>Adult T-cell leukemia/lymphoma</strong> (ATL) is is a rare and aggressive <a href=\"http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&amp;b=6300161\" target=\"_blank\">T-cell lymphoma</a> that is linked to infection by the <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=269419\" target=\"_blank\">human T-cell lymphotropic virus 1 (HTLV-1)</a>.[12192][12194] The exact mechanism by which HTLV-I infection causes the ATL is unknown. The clinical features of ATL include generalized swelling of the lymph nodes (<a href=\"http://www.webmd.com/a-to-z-guides/swollen-lymph-nodes-topic-overview\" target=\"_blank\">lymphadenopathy</a>), increased liver and spleen size (<a href=\"https://medlineplus.gov/ency/imagepages/17215.htm\" target=\"_blank\">hepatosplenomegaly</a>), immunosuppression, high levels of calcium in the blood, lytic bone lesions (spots that appear as &ldquo;holes&rdquo; on a standard bone x-ray), and skin lesions. &nbsp;There are four basic clinical variants of ATL: acute (60% of cases), lymphomatous (20 % of cases), chronic (10% of cases) and smoldering (10% of cases).[12192] The best treatment for these patients is unclear and patients should be enrolled in clinical trials whenever possible. Medication may include <a href=\"https://www.macmillan.org.uk/cancerinformation/cancertreatment/treatmenttypes/chemotherapy/combinationregimen/chop.aspx\" target=\"_blank\">CHOP chemotherapy&nbsp;</a>(cyclophosphamide, doxorubicin, vincristine and prednisone) or <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=38921\" target=\"_blank\">EPOCH</a> (etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone). In some patients, a <a href=\"https://medlineplus.gov/bonemarrowtransplantation.html\" target=\"_blank\">bone marrow transplant</a> may be recommended.[12194][12193]","dateModified":"2016-09-13T10:18:00"},"basicQuestions":[],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"Adult_T-cell_leukemia_lymphoma"}